| Literature DB >> 15935730 |
Beatriz M Carreno1, Laura L Carter, Mary Collins.
Abstract
The CD28 and B7 protein families are critical regulators of immune responses and, in the past few years, several new family members have been identified. Preclinical studies exploring the role of members of the CD28 and B7 families support the targeting of these pathways for new therapeutic approaches. Indeed, recent Phase I clinical studies using agonists and antagonists of the CD28/CTLA-4/B7 pathway have shown promise in inflammatory diseases and cancer.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15935730 DOI： 10.1016/j.coph.2005.02.003
Source DB: PubMed Journal: Curr Opin Pharmacol ISSN： 1471-4892 Impact factor: 5.547